Clinical Research Directory
Browse clinical research sites, groups, and studies.
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Sponsor: Tang-Du Hospital
Summary
The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.
Official title: A Randomized Control Trial of Baricitinib Administration in Patients With Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-11-24
Completion Date
2026-12-31
Last Updated
2025-06-04
Healthy Volunteers
No
Conditions
Interventions
Baricitinib 4 MG
Baricitinib with be be administrated orally (or crushed for nasogastric tube delivery) and given daily at the dosage of 4mg for consecutive 14 days
Standard treatment
Patients will receive standard treatment and care according to the current management guidelines for traumatic brain injury.
Locations (1)
Tandu Hospital, Fourth Military Medical University
Xi'an, Shaanxi, China